These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 19640960)

  • 1. Alcohol consumption and diabetes risk in the Diabetes Prevention Program.
    Crandall JP; Polsky S; Howard AA; Perreault L; Bray GA; Barrett-Connor E; Brown-Friday J; Whittington T; Foo S; Ma Y; Edelstein SL;
    Am J Clin Nutr; 2009 Sep; 90(3):595-601. PubMed ID: 19640960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin.
    Kitabchi AE; Temprosa M; Knowler WC; Kahn SE; Fowler SE; Haffner SM; Andres R; Saudek C; Edelstein SL; Arakaki R; Murphy MB; Shamoon H;
    Diabetes; 2005 Aug; 54(8):2404-14. PubMed ID: 16046308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of anti-IL-1β antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial.
    Rissanen A; Howard CP; Botha J; Thuren T;
    Diabetes Obes Metab; 2012 Dec; 14(12):1088-96. PubMed ID: 22726220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship of body size and shape to the development of diabetes in the diabetes prevention program.
    Diabetes Prevention Program Research Group
    Obesity (Silver Spring); 2006 Nov; 14(11):2107-17. PubMed ID: 17135629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic syndrome components and their response to lifestyle and metformin interventions are associated with differences in diabetes risk in persons with impaired glucose tolerance.
    Florez H; Temprosa MG; Orchard TJ; Mather KJ; Marcovina SM; Barrett-Connor E; Horton E; Saudek C; Pi-Sunyer XF; Ratner RE; Goldberg RB;
    Diabetes Obes Metab; 2014 Apr; 16(4):326-33. PubMed ID: 24118860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Steps toward the primary prevention of type II diabetes mellitus. Various epidemiological considerations].
    Flórez H
    Invest Clin; 1997 Mar; 38(1):39-52. PubMed ID: 9235072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes.
    Freemark M; Bursey D
    Pediatrics; 2001 Apr; 107(4):E55. PubMed ID: 11335776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes.
    Goldberg RB; Temprosa MG; Mather KJ; Orchard TJ; Kitabchi AE; Watson KE;
    Diabetes Care; 2014 Aug; 37(8):2253-60. PubMed ID: 24824548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of 1-year treatment with metformin on metabolic and cardiovascular risk factors in non-diabetic upper-body obese subjects with mild glucose anomalies: a post-hoc analysis of the BIGPRO1 trial.
    Fontbonne A; Diouf I; Baccara-Dinet M; Eschwege E; Charles MA
    Diabetes Metab; 2009 Nov; 35(5):385-91. PubMed ID: 19665415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Progress in the prevention of type 2 diabetes].
    Schernthaner G
    Wien Klin Wochenschr; 2003 Nov; 115(21-22):745-57. PubMed ID: 14743578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Lifestyle and Metformin Interventions on the Risk of Progression to Diabetes and Regression to Normal Glucose Regulation in Overweight or Obese People With Impaired Glucose Regulation.
    Herman WH; Pan Q; Edelstein SL; Mather KJ; Perreault L; Barrett-Connor E; Dabelea DM; Horton E; Kahn SE; Knowler WC; Lorenzo C; Pi-Sunyer X; Venditti E; Ye W;
    Diabetes Care; 2017 Dec; 40(12):1668-1677. PubMed ID: 29021207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of progression from impaired glucose tolerance to diabetes on cardiovascular risk factors and its amelioration by lifestyle and metformin intervention: the Diabetes Prevention Program randomized trial by the Diabetes Prevention Program Research Group.
    Goldberg RB; Temprosa M; Haffner S; Orchard TJ; Ratner RE; Fowler SE; Mather K; Marcovina S; Saudek C; Matulik MJ; Price D;
    Diabetes Care; 2009 Apr; 32(4):726-32. PubMed ID: 19171717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
    ; Knowler WC; Fowler SE; Hamman RF; Christophi CA; Hoffman HJ; Brenneman AT; Brown-Friday JO; Goldberg R; Venditti E; Nathan DM
    Lancet; 2009 Nov; 374(9702):1677-86. PubMed ID: 19878986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Change in adiponectin explains most of the change in HDL particles induced by lifestyle intervention but not metformin treatment in the Diabetes Prevention Program.
    Goldberg RB; Temprosa M; Mele L; Orchard T; Mather K; Bray G; Horton E; Kitabchi A; Krakoff J; Marcovina S; Perreault L; White N;
    Metabolism; 2016 May; 65(5):764-775. PubMed ID: 27085783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regression from pre-diabetes to normal glucose regulation in the diabetes prevention program.
    Perreault L; Kahn SE; Christophi CA; Knowler WC; Hamman RF;
    Diabetes Care; 2009 Sep; 32(9):1583-8. PubMed ID: 19587364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study.
    Zinman B; Harris SB; Neuman J; Gerstein HC; Retnakaran RR; Raboud J; Qi Y; Hanley AJ
    Lancet; 2010 Jul; 376(9735):103-11. PubMed ID: 20605202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study.
    Perreault L; Pan Q; Mather KJ; Watson KE; Hamman RF; Kahn SE;
    Lancet; 2012 Jun; 379(9833):2243-51. PubMed ID: 22683134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and effectiveness of metformin plus lifestyle intervention compared with lifestyle intervention alone in preventing progression to diabetes in a Chinese population with impaired glucose regulation: a multicentre, open-label, randomised controlled trial.
    Zhang L; Zhang Y; Shen S; Wang X; Dong L; Li Q; Ren W; Li Y; Bai J; Gong Q; Kuang H; Qi L; Lu Q; Cheng W; Liu Y; Yan S; Wu D; Fang H; Hou F; Wang Y; Yang Z; Lian X; Du J; Sun N; Ji L; Li G;
    Lancet Diabetes Endocrinol; 2023 Aug; 11(8):567-577. PubMed ID: 37414069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions.
    Ratner RE; Christophi CA; Metzger BE; Dabelea D; Bennett PH; Pi-Sunyer X; Fowler S; Kahn SE;
    J Clin Endocrinol Metab; 2008 Dec; 93(12):4774-9. PubMed ID: 18826999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-traditional biomarkers and incident diabetes in the Diabetes Prevention Program: comparative effects of lifestyle and metformin interventions.
    Goldberg RB; Bray GA; Marcovina SM; Mather KJ; Orchard TJ; Perreault L; Temprosa M;
    Diabetologia; 2019 Jan; 62(1):58-69. PubMed ID: 30334082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.